FDA Approves TIVICAY PD — ViiV Healthcare Company

ViiV Healthcare announced Tuesday the FDA approval of TIVICAY PD (dolutegravir sodium), the company's long-acting, injectable formulation of the HIV integration inhibitor. This novel delivery mechanism offers a potential shift toward quarterly dosing, allowing patients to forgo daily pills and signaling a significant expansion into the long-acting antiretroviral market space.